Noven To Present at Thomas Weisel Partners Healthcare Conference

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that Robert C. Strauss, its President, CEO & Chairman, is scheduled to provide an update on Noven’s business and prospects at the Thomas Weisel Partners Healthcare Conference in Boston on Wednesday, September 6, 2006, at 10:55 a.m. Eastern Time. The public is invited to listen to the presentation live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven’s prescription patches are approved in over 30 countries and include Vivelle-Dot™ (the most prescribed estrogen patch in the U.S.) and Daytrana™ (the first and only patch approved for the treatment of ADHD). A range of new patches is being investigated and developed in collaboration with Shire plc, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916